Advances in the management of gastroparesis

Current Treatment Options in Gastroenterology

Volumn 10, Issue 4, 2007, Pages 283-293

  Friedenberg, Frank K ^b   Parkman, Henry P ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; APREPITANT; BETHANECHOL; BOTULINUM TOXIN; CISAPRIDE; CLONIDINE; COMPRAZINE; DIPHENHYDRAMINE; DOLASETRON MESILATE; DOMPERIDONE; DOPAMINE; ERYTHROMYCIN; GLUCOSE; GRANISETRON; MECLOZINE; METOCLOPRAMIDE; MEVINOLIN; ONDANSETRON; PALONOSETRON; PLACEBO; PROCHLORPERAZINE; PROKINETIC AGENT; PROMETHAZINE; SCOPOLAMINE; SEROTONIN 3 ANTAGONIST; SILDENAFIL; SUMATRIPTAN; TECHNETIUM SULFUR COLLOID TC 99M; TEGASEROD; TRIMETHOBENZAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL CRAMP; ABDOMINAL PAIN; AMENORRHEA; ANGINA PECTORIS; CALORIC INTAKE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DEPRESSION; DIABETES MELLITUS; DIET RESTRICTION; DIET THERAPY; DIETARY INTAKE; DROWSINESS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSTONIA; ELECTROLYTE BALANCE; FAT INTAKE; FLUID INTAKE; FOOD AND DRUG ADMINISTRATION; GALACTORRHEA; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GYNECOMASTIA; HEART ARRHYTHMIA; HEART INFARCTION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; IMPOTENCE; IRRITABLE COLON; JEJUNOSTOMY; LOW DRUG DOSE; NAUSEA; NAUSEA AND VOMITING; NUTRITIONAL DEFICIENCY; OBSTRUCTIVE JAUNDICE; PARKINSONISM; PATHOGENESIS; QT PROLONGATION; REVIEW; RISK FACTOR; SEDATION; SIDE EFFECT; STOMACH EMPTYING; STOMACH PARESIS; SYMPTOMATOLOGY; TACHYPHYLAXIS; TARDIVE DYSKINESIA; TORSADE DES POINTES; TREMOR; VOMITING;

EID: 34547595459     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-007-0071-6     Document Type: Review

References (35)

1. He CL, Soffer EE, Ferris CD, et al.: Loss of interstitial cells of cajal and inhibitory innervation in insulin-dependent diabetes. Gastroenterology 2001, 121:427-434.
2. Sarnelli G, Caenepeel P, Geypens B, et al.: Symptoms associated with impaired gastric emptying of solids and liquids in functional dyspepsia Am J Gastroenterol 2003, 98:783-788.
3. Lemann M, Dederding JP, Flourie B, et al.: Abnormal perception of visceral pain in response to gastric distension in chronic idiopathic dyspepsia. Dig Dis Sci 1991, 36:1249-1254.
4. Parkman HP, Harris AD, Krevsky B, er al.: Gastroduodenal motility and dysmotility: update on techniques available for evaluation Am J Gastroenterol 1995, 90:869-892.
5. Thomforde GM, Camilleri M, Phillips SF, Forstrom LA: Evaluation of an inexpensive screening scintigraphic test of gastric emptying. J Nucl Med 1995, 36:93-96.
6. Guo JP, Maurer AH, Fisher RS, Parkman HP: Extending gastric emptying scintigraphy from two to four hours detects more patients with gastroparesis. Dig Dis Sci 2001, 46:24-29.
7. Tougas G, Eaker EY, Abell TL, et al.: Assessment of gastric emptying using a low fat meal: establishment of international control values. Am J Gastroenterol 2000, 95:1456-1462.
8. Kuo B, McCallum RW, Koch KL, et al.: SmartPill, a novel ambulatory diagnostic test for measuring gastric emptying in health and disease [abstract]. Gastroenterology 2006, 130 (4 Suppl 1):A434.
9. Bromer MQ, Kantor SN, Wagner DA, et al.: Simultaneous measurement of gastric emptying with a simple muffin meal using 13C-octanocate breath test and scintigraphy in normal subjects and patients with in dyspeptic symptoms. Dig Dis Sci 2002, 47:1657-1663.
10. Fontana RJ, Barnett JL: Jejunostomy tube placement in refractory diabetic gastroparesis: a retrospective review. Am J Gastroenterol 1996, 91:2174-2178.
11. Friedenberg F, Parkman HP: Management of delayed gastric emptying. Clin Gastroenterol Hepatol 2005, 3:642-646.
12. Rayner CK, Samsom M, Jones KL, Horowitz M: Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care 2001, 24:371-381.
13. Fraser RJ, Horowitz M, Maddox AF, et al.: Hyperglycaemia slows gastric emptying in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1990, 33:675-680.
14. Brownlee M, Kroopf SS: Metoclopramide for gastroparesis diabeticorum. N Engl J Med 1974, 291:1257-1258.
15. McCallum RW, Ricci DA, Rakatansky H, et al.: A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care 1983, 6:463-467.
16. Ganzini L, Casey DE, Hoffman WF, McCall AL: The prevalence of metodopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med 1993, 153:1469-1475.
17. Miller LG, Jankovic J: Metoclopramide-induced movement disorders. Clinical findings with a review of the literature. Arch Intern Med 1989, 149:2486-2492.
18. Patterson D, Abell T, Rothstein R, et al.: A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol 1999, 94:1230-1234.
19. Warts GF, Armitage M, Sinclair J, Hill JD: Treatment of diabetic gastroparesis with oral domperidone. Diabet Med 1985, 2:491-492.
20. DiBaise JK, Quigley EM: Efficacy of prolonged administration of intravenous erythromycin in an ambulatory setting as treatment of severe gastroparesis. J Clin Gastroenterol 1999, 28:131-134.
21. Maganti K, Onyemere K, Jones MP: Oral erythromycin and symptomatic relief of gastroparesis: a systematic review. Am J Gastroenterol 2003, 98:259-263.
22. Erbas T, Varoglu E, Erbas B, et al.: Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis. Diabetes Care 1993, 16:1511-1514.
23. Di Stefano M, Vos R, Janssens J, Tack JF: Effect of tegaserod, a 5-HT4 receptor partial agonist, on interdigestive and postprandial gastrointestinal motility in healthy volunteers [abstract]. Gastroenterology 2003, 124:A163.
24. Degen L, Matzinger D, Merz M, et al.: Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects Aliment Pharmacol Ther 2001, 15:1745-1751.
25. Tougas G, Chen Y, Luo D, et al.: Tegaserod improves gastric emptying in patients with gastroparesis and dyspeptic symptoms [abstract]. Gastroenterology 2003, 124: A54-A68.
26. Bromer MQ, Friedenberg F, Miller LS, et al.: Endoscopic pyloric injection of botulinum toxin A for the treatment of refractory gastroparesis. Gastrointest Endosc 2005, 61:833-839.
27. Miller LS, Szych GA, Kantor SB, et al.: Treatment of idiopathic gastroparesis with injection of botalinum toxin into the pyloric sphincter muscle. Am J Gastroenterol 2002, 97: 1653-1660.
28. Friedenberg F, Gollamudi S, Parkman HP: Review: the use of botulinum toxin for the treatment of gastrointestinal motility disorders. Dig Dis Sci 2004, 2:165-175.
29. Hotokezaka M, Adams RB, Miller AD, et al.: Laparoscopic percutaneous jejunostomy for long term enteral access. Surg Endosc 1996, 10:1008-1011.
30. Abell T, McCallum R, Hocking M, et al.: Gastric electrical stimulation for medically refractory gastroparesis. Gastroenterology 2003, 125:421-428.
31. Thumshirn M, Camilleri M, Cho MG, Zinsmeister AR: Modulation of gastric sensory and motor functions by nitrergic and alpha-2 adrenergic agents Gastroenterology 1999, 116:573-585.
32. Rosa-e-Silva L, Troncon LE, Oliveira RB, et al.: Treatment of diabetic gastroparesis with oral clonidine. Aliment Pharmacol Ther 1995, 9:179-183.
33. Tack J, Coulie B, Andrioli A, Janssens J: Influence of sumatriptan on gastric fundus tone and of the perception of gastric distension in man. Gut 2000, 46:468-473.
34. Sarnelli G, Vos R, Sifrim D, et al.: Influence of sildenafil on fasting and postprandial gastric tone in man [abstract]. Gastroenterology 2001, 120:A285-A286.
35. de Rosalmeida MC, Saraiva LD, da Graca JR, et al.: Sildenafil, a phosphodiesterase-5 inhibitor, delays gastric emptying and gastrointestinal transit of liquid in awake rats. Dig Dis Sci 2003, 48:2064-2068.